Table 2. Main results for meta-analysis between SOX2 and clinicopathological Parameters.
clinical parameters | No. of studies | overall OR (95%CI) | Heterogeneity test (Q, I2, P) |
Sex (male vs. female) | (1),(4),(5),(6),(7) | 1.49 (0.69–3.23) | 10.6, 62.3%, 0.312 (random-effect) |
Age (>60 vs. < = 60) | (1),(5),(6),(7) | 1.30 (0.84–2.01) | 3.88, 22.7%, 0.236 (fixed-effect) |
Smoking status (yes vs. no) | (1),(4),(5),(7) | 2.40 (0.95–6.05) | 6.79, 55.8%, 0.065 (random-effect) |
Histology (SCCvs. ADC) | (2),(3),(4),(5),(6),(7) | 5.26 (1.08–25.6) | 78.2, 93.6%, 0.040 (random-effect) |
Differentiation (poor vs. well) | (5),(6),(7) | 1.97 (0.96–4.05) | 0.49, 0.0%, 0.066 (fixed-effect) |
Lyphmnodemetastsis (N1 vs. N0) | (4),(5),(7) | 1.30 (0.85–1.97) | 1.48, 0.0%, 0.226 (fixed-effect) |
Stage (III/IV vs. I/II) | (4),(6),(7) | 0.89 (0.55–1.44) | 2.08, 3.9%, 0.621 (fixed-effect) |
Abbreviations: SCC, squamous cell carcinomas; ADC, adenocarcinomas; OR, odds ratios.